Indications for Use:

Dabigatran PSK is indicated for use in adults aged 18 years and older:

• Prevention of stroke, systemic thromboembolism and reduction of cardiovascular mortality in adult patients with non-valvular atrial fibrillation and one or more risk factors such as a history of stroke or transient ischemic attack (TIA), age 75 years and older, chronic heart failure (≥ NYHA functional class II or higher), diabetes mellitus, arterial hypertension, vascular disease (previous myocardial infarction, peripheral arterial disease or atherosclerotic plaque in the aorta).

• Treatment and prevention of recurrent acute deep vein thrombosis (DVT) and/or pulmonary embolism (PTE) and prevention of deaths caused by these diseases.

This product is included in the Essential Drug List (EDL).

THERE ARE CONTRAINDICATIONS AND DRUG INTERACTIONS. PLEASE CONSULT A SPECIALIST BEFORE USE.

For the full version of the Dabigatran PSK (dabigatran) leaflet, please visit this website: https://grls.rosminzdrav.ru/Default.aspx